Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Interleukin-1 receptor-associated kinases (IRAKs) are important mediators in the signal transduction of Toll/IL-1 receptor (TIR) family members. Dysregulation of TIR signaling, typified by increased NF-κB activity, results in the development of some cancers and other diseases, making the development of IRAK inhibitors a potential therapeutic strategy. IRAK1/4 inhibitor is a benzimidazole that disrupts the activity of IRAK 1 and 4 with IC50 values of 0.3 and 0.2 µM, respectively.1 It demonstrates IC50 values >10 µM in a panel of 27 other kinases tested.1 This compound has been used to inhibit a pro-inflammatory response in microglia isolated from clinically diagnosed Alzheimer’s disease patients.2
WARNING This product is not for human or veterinary use.
1. Discovery and initial SAR of inhibitors of interleukin-
2. Increased IRAK-